TEGRETOL
LOE ApproachingNDAORALTABLET, CHEWABLE
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TEGRETOL by Novartis is mechanism of action tegretol has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures. Approved for the treatment of the pain associated with true trigeminal neuralgia. First approved in 1981.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEGRETOL (carbamazepine) is a small-molecule anticonvulsant approved in 1981 for seizure disorders and neuropathic pain conditions. The drug works by stabilizing sodium channels and reducing neuronal firing, making it effective across multiple neurological indications. It is available as oral tablets and chewable formulations for chronic use in epilepsy and off-label applications.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the brand team is likely consolidating and transitioning to post-exclusivity defense strategies.
Mechanism of Action
Mechanism of Action Tegretol has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. Tegretol greatly reduces or abolishes pain induced by…
Worked on TEGRETOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.